Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene ef... | ResearchHub
Paper
Paper
Search...
Search ResearchHub...
Ctrl+K
New
Home
Browse
Earn
Fund
RH Journal
Notebook
Lists
Leaderboard
RSC
USD
Changelog
Terms
Privacy
Issues
Docs
Support
Foundation
About
CRISPR/Cas9 technology abolishes the BCR/ABL1 oncogene effect in chronic myeloid leukemia and restores normal hematopoiesis
0
Authors
Elena Vuelta
14 more
Elena Vuelta
•
José Ordóñez
12 more
•
Manuel Sánchez‐Martín
Published
September 4, 2020
Paper
Conversation
0
Reviews
0
Bounties
0
Sign in to review
Share your thoughts on this paper...
Best
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Immunology
Hematology
Genetics
Show all topics
DOI
10.1101/2020.08.05.237610
License
CC-BY-NC-ND
Other Formats
PDF
Supporters
Support the authors with ResearchCoin
Tip RSC
Preprint Server
Topics
Biology
Cancer Oncology
Immunology
Hematology
Genetics
Show all topics
DOI
10.1101/2020.08.05.237610
License
CC-BY-NC-ND
Other Formats
PDF
